I presume, if they can renegotiate the safety aspect to be far less onerous with the FDA, it opens up an extremely efficient pathway to develop the entire pipeline of candidates.
That would be a massive gain for a potential suitor. So another strategy to improve an eventual pricing of NEU takeover. And may be done by end of year?
NEU Price at posting:
$23.20 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)